Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Chinese in oncology

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 13, 2022 2:13pm

269 Views

Post# 34424555

RE:Chinese in oncology

Of note in this article are those candidates in which ONCY has particular interests for combination / co-therapies and are listed as the biologicals in focus for Chinese oncology R&D :

Biologics are the focus

A big chunk of the oncology drug candidates in China are biologics, which include monoclonal antibodies, ADC, therapeutic vaccines, oncolytic virus, and cell therapy.

<< Previous

Bullboard Posts

Next >>

Nintendo stock jumps despite Q2 financials, new console news